Related Experiment Videos
[Cholestatic hepatosis caused by Talinolol (Cordanum)?]
Zeitschrift Fur Die Gesamte Innere Medizin Und Ihre Grenzgebiete
|January 15, 1979
Summary
Talinolol, a medication, caused liver injury in a patient presenting with cholestatic hepatosis. This adverse drug reaction was confirmed through specific immune tests and re-exposure, highlighting potential liver function burdens.
Area of Science:
- Hepatology
- Clinical Pharmacology
- Immunotoxicology
Background:
- Beta-blockers, like talinolol, are widely prescribed for cardiovascular conditions.
- Drug-induced liver injury (DILI) is a significant clinical concern, often presenting with cholestatic features.
- Understanding the mechanisms of DILI is crucial for patient safety and drug development.
Observation:
- A 38-year-old female developed dyspeptic symptoms and cholestasis after 18 days of talinolol treatment (150 mg/day).
- Liver biopsy revealed a cholestatic hepatosis pattern.
- Immune response tests, including lymphocyte transformation and monocyte tests, were positive for talinolol.
Findings:
- Talinolol was identified as the causative agent for the observed cholestatic hepatosis.
- Re-exposure to talinolol resulted in clinical relapse, confirming the drug's role.
- Pathogenesis may involve structural similarities to para-group substances and cumulative liver stress.
Implications:
- This case underscores the potential for talinolol to induce significant liver injury.
- It highlights the importance of considering drug-induced hepatotoxicity in patients with unexplained cholestasis.
- Further investigation into talinolol's hepatotoxic mechanisms and risk factors is warranted.